Journal profile · Cardiac & Cardiovascular Systems
Cardiovascular Drugs and Therapy
ISSN 0920-3206 · eISSN 1573-7241 · Springer US · UNITED STATES · Bimonthly · Founded 1987
Cardiovascular Drugs and Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.42; hybrid open access; APC about USD 4,490; median 57 days to acceptance (55 articles, last 24 months); community-reported acceptance: about 67.5%; 161 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cardiovascular Drugs and Therapy is published by Springer US and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cardiac electrophysiology and arrhythmias, Heart Failure Treatment and Management and Cardiovascular Function and Risk Factors, together about 25.6% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Cardiovascular Drugs and Therapy focuses on bench to bedside development of innovative clinical management strategies for cardiovascular disease. By reporting exciting advances in discovery research through to clinical trials, the journal provides an authoritative platform for dissemination and critical discussion in this rapidly evolving field. Centered on the most innovative research and development of novel therapeutic approaches, Cardiovascular Drugs and Therapy objectively focuses on progress in detection, treatment and prevention of cardiometabolic disease, atherosclerosis, ischemic syndromes, heart failure, cardiomyopathies, valvular heart disease, arrhythmias, and vascular dysfunction. Specific consideration is given to discovery of underlying signaling pathways, their potential for new drug development, novel indications for older drugs, and genetic approaches. Focus on new directions in device and cell therapy, interventional and structural heart disease, and cardiac and vascular surgery, as well as their guideline-based utilization in real-world patient populations, promotes direct practical relevance. The journal particularly welcomes original research articles incorporating mechanistic focus, prospective clinical studies and trials, innovative meta-analyses clarifying inconclusive or conflicting evidence, and expert critical reviews. Cardiovascular Drugs and Therapy is listed in Web of Science and PubMed/Medline among other abstracting and indexing services. Regular publication of original research articles and reviews alongside topical discussions position the journal as an authoritative source of current advances in translational cardiovascular research for both discovery scientists and clinicians.
From the journal's Aims & Scope
Research area (LetPub): Cardiac & Cardiovascular Systems
Editor-in-chief David GrievePublisher website
Editorial board by country: 3 in mainland China (about 4%); most named United States 27, United Kingdom 6, Japan 6, Australia 5, Germany 4 (68 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cardiac electrophysiology and arrhythmiasMedicine10.1%
- Heart Failure Treatment and ManagementMedicine8%
- Cardiovascular Function and Risk FactorsMedicine7.5%
- Cardiac Ischemia and ReperfusionMedicine7.4%
- Blood Pressure and Hypertension StudiesMedicine6.1%
- Lipoproteins and Cardiovascular HealthMedicine5.9%
- Atrial Fibrillation Management and OutcomesMedicine5.3%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Cardiac & Cardiovascular Systems | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.42LetPub ·
- Impact factor (publisher) 2025
- 3.5Publisher website ·
- 5-year impact factor (publisher) 2025
- 3.7Publisher website ·
- CiteScore 2026-06
- 9LetPub ·
- SJR 2026-06
- 1.02LetPub ·
- SNIP 2026-06
- 1LetPub ·
- h-index
- 63LetPub ·
- h-index
- 98OpenAlex ·
- i10-index
- 1,808OpenAlex ·
- 2-year mean citedness
- 2.88OpenAlex ·
- Self-citation rate
- 11.4%LetPub ·
- Share of gold OA articles
- 27.34%LetPub ·
Volume
- Articles per year
- 91LetPub ·
- Downloads per year (publisher) 2025
- 694,300Publisher website ·
Articles by year OpenAlex count · 3,982 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 136 | 25 | 59 |
| 2025 | 161 | 53 | 461 |
| 2024 | 121 | 50 | 683 |
| 2023 | 122 | 54 | 989 |
| 2022 | 127 | 54 | 1,794 |
| 2021 | 171 | 76 | 3,036 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
57 daysMedian, submission to acceptance · P25–P75 15 days – 99 days
- Acceptance to online
- median 11 days (110 articles)
- Submission to online
- median 72 days
- Sample
- 55 articles with submission and acceptance dates (325 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 4.5 monthsLetPub ·
- Average acceptance (community reports)
- 67.5%LetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,490 / EUR 3,690 / GBP 2,990 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- Charged; see the journal's website for the amount
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Manuscript length
- ≤ 5,000 words
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Not considered
- Case reports; Uncontrolled studies
Article types accepted16, with length limits
- case reportThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- editorialThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…main text ≤ 2,400 words · figures and tables ≤ 2 · references ≤ 15
- hypothesisThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- letterThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…main text ≤ 1,000 words
- letters to the editorThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…main text ≤ 1,000 words · references ≤ 5
- original articleThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- original research articleThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…main text ≤ 5,000 words
- original research articlesOriginal articles should not exceed 5000 words, figure legends and references not included. References should be of recent date and not exceed 50.main text ≤ 5,000 words · references ≤ 50
- protocolThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- regular research articleThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- reviewThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- review articleThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…Length not stated
- review articlesThere is no fixed limit on the length of review articles, though concise presentation is expected.Length not stated
- short communicationThe Journal welcomes original articles dealing with basic pharmacology, clinical drug studies and large controlled trials, related to cardiovascular drug, devic…main text ≤ 2,500 words · figures and tables ≤ 2 · references ≤ 15
- short communicationsShort Communications should follow the same general rules as regular research articles, but should not exceed 2500 words and contain no more than 15 references.…main text ≤ 2,500 words · figures and tables ≤ 2 · references ≤ 15
- trial designsTrial Design papers should be concise and focused descriptions of the study protocol, including the background underlying the hypotheses, the primary and second…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- AI use Generative AI Images
LLMs do not satisfy authorship criteria; use of an LLM should be documented in the Methods section. Model summary
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein.
Source ↗Publisher website ·- Authorship Authorship principles
4 to 6 keywords for indexing purposes. Model summary
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
The journal is a member of COPE and follows COPE guidelines on misconduct. Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Permission from copyright owners is required for previously published figures, tables, or text passages. Model summary
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Cardiovascular Drugs and Therapy, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time…
Source ↗Publisher website ·- Plagiarism
The journal may use software to screen for plagiarism. Model summary
Important note: the journal may use software to screen for plagiarism.
Source ↗Publisher website ·- Preprints
Pre-submission enquiries are not supported; all contributions must be submitted via EditorialManager. Model summary
Please note that the Journal does not suport pre-submission. All contributions have to be submitted via EditorialManager.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1987
- ISSN
- 0920-3206
- Electronic ISSN
- 1573-7241
- Latest issue on the website
- Volume 40, Issue 4 (August 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cardiovascular Drugs and Therapy
What CAS zone is Cardiovascular Drugs and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cardiovascular Drugs and Therapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy / Cardiac & Cardiovascular Systems. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cardiovascular Drugs and Therapy?
The latest impact factor listed by LetPub is 3.42; CiteScore 9, h-index 98.
How long does peer review take at Cardiovascular Drugs and Therapy?
Based on the dates recorded on 55 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 57 days (interquartile range 15–99 days); authors report an average review time of about 4.5 months; the community-reported acceptance is “about 67.5%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cardiovascular Drugs and Therapy?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Manuscript length: ≤ 5,000 words; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cardiovascular Drugs and Therapy based?
Of the 68 board members whose country the journal's board page names, 3 (about 4%) are in mainland China; the countries named most often are United States (27), United Kingdom (6) and Japan (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Cardiovascular Drugs and Therapy?
According to LetPub and DOAJ records, Cardiovascular Drugs and Therapy is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Cardiovascular Drugs and Therapy open access, and what is the APC?
Cardiovascular Drugs and Therapy is a hybrid journal. For open-access publication: APC about USD 4,490.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .